Sharper definitions, blurred lines: The clinical aftermath of the revised antiphospholipid syndrome criteria

Ähnliche Einträge

• A paradigm shift in neutrophil adverse event grading: What now?
  von: Lauren E. Merz
  Veröffentlicht: (2025)
• Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real‐world patients
  von: Claudia Bellofiore, et al.
  Veröffentlicht: (2026)
• Medical haematology trial eligibility and the Duffy null‐associated neutrophil count: A cross‐sectional study
  von: Olga Tsiamita, et al.
  Veröffentlicht: (2025)
• Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
  von: Fabio Efficace, et al.
  Veröffentlicht: (2024)
• Should the current diagnostic criteria for CLL be reconsidered? A reply to Johnstone et al. “De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria”
  von: Daniel Mazza Matos
  Veröffentlicht: (2026)